Fujifilm Toyama Chemical has started a Phase III clinical trial of its antiviral influenza drug Avigan (favipiravir) for the treatment of Covid-19 patients in Japan.
Avigan specifically blocks RNA polymerase associated with influenza viral replication.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The mechanism is expected to have an antiviral effect on SARS-CoV-2, the novel coronavirus that causes Covid-19.
